Tempus AI (NASDAQ:TEM) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM) in a research report report published on Tuesday,Benzinga reports. Needham & Company LLC currently has a $56.00 price objective on the stock.

TEM has been the topic of several other reports. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the company from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital upped their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, Piper Sandler reiterated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.36.

Tempus AI Trading Down 1.6 %

NASDAQ TEM opened at $31.83 on Tuesday. The business’s 50-day moving average price is $47.94 and its two-hundred day moving average price is $47.28. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49.

Insider Transactions at Tempus AI

In related news, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares in the company, valued at $694,263,084.55. This trade represents a 2.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Ryan Fukushima sold 120,000 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the completion of the sale, the chief operating officer now directly owns 1,007,207 shares of the company’s stock, valued at approximately $42,816,369.57. The trade was a 10.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 865,041 shares of company stock valued at $35,917,673 in the last 90 days.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC acquired a new position in Tempus AI during the 4th quarter valued at about $67,000. Green Alpha Advisors LLC purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $1,090,000. Silverleafe Capital Partners LLC purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $533,000. Franklin Resources Inc. grew its holdings in Tempus AI by 1.0% during the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock worth $45,920,000 after buying an additional 8,387 shares in the last quarter. Finally, Tidal Investments LLC purchased a new stake in Tempus AI in the 3rd quarter valued at $7,633,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.